{"analyses":[{"ciLowerLimit":"0.500","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.968","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0302","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.70","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.8","upperLimit":"33.4","value":"29.9"},{"groupId":"OG001","lowerLimit":"19.5","upperLimit":"25.9","value":"22.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.","id":"OG000","title":"gBRCA Niraparib"},{"description":"Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.","id":"OG001","title":"gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days","title":"Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)","type":"SECONDARY","unitOfMeasure":"Months"}